As a protein therapy expert, Five Prime Therapeutics continues to develop their library of more than 5,700 human extracellular proteins. The company maintains a library that has virtually all of the important proteins needed in medicine.

Through the protein screening technologies owned by the company, they were able to further advance the future of protein therapeutics. This strong knowledge and their extensive collection of protein samples allow the company to start their discovery and development of novelty therapeutics for cancer and other inflammatory diseases. There are currently three lead product candidates that the business is developing. These therapeutics include FPA008, FP-1039/GSK3052230 and FPA144. These products are intended to treat various forms of cancer.

Five Prime Therapeutics has very strong partnerships with other companies including Bristol-Myers Squibb, UCB Pharm and GlaxoSmithKline. The company is headquartered in South San Francisco, California. It remains to be publicly traded on the NASDAQ (FPRX) and is listed as a component of the Wilshire 5000 Index.